Abstract
Background: In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [18F]Fluoro-Methyl Choline ([18F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT). Methods: Patients with biochemical recurrence limited up to three lesions revealed by [18F]FMCH PET/CT were enrolled in the present study and treated with SBRT on all active lesions. Systemic therapy-free survival since the [18F]FMCH PET/CT was considered as the primary endpoint. Results: Forty-six patients were evaluated, and a total of 67 lesions were treated. After a median follow-up of 28.9 months, systemic therapy was started in 30 patients (65.2%) and median systemic therapy-free survival was 39.1 months (95% CI 6.5–68.6); 6, 12, and 24-month ratios were 93.5%, 73.9%, and 63.1%, respectively. At univariate Cox regression analysis, Delta PSA demonstrated an impact on systemic therapy-free survival (p < 0.001). Conclusions: Based on our findings, [18F]FMCH PET/CT can identify oligometastatic prostate cancer patients suitable for SBRT, resulting in a systemic therapy-free survival of 39.1 months.
| Original language | English |
|---|---|
| Pages (from-to) | 185-191 |
| Number of pages | 7 |
| Journal | European Journal of Nuclear Medicine and Molecular Imaging |
| Volume | 47 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1 2020 |
Fingerprint
Keywords
- Prostate cancer
- Stereotactic body radiotherapy
- [F]FMCH PET/CT
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
[18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer. / Pasqualetti, Francesco; Panichi, Marco; Sollini, Martina; Sainato, Aldo; Galli, Luca; Morganti, Riccardo; Chiacchio, Serena; Marciano, Andrea; Zanca, Roberta; Mannelli, Lorenzo; Coraggio, Gabriele; Sbrana, Andrea; Cocuzza, Paola; Montrone, Sabrina; Baldaccini, Davide; Gonnelli, Alessandra; Molinari, Alessandro; Cantarella, Martina; Mazzotti, Valentina; Ricci, Sergio; Paiar, Fabiola; Erba, Paola Anna.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 47, No. 1, 01.01.2020, p. 185-191.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - [18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer
AU - Pasqualetti, Francesco
AU - Panichi, Marco
AU - Sollini, Martina
AU - Sainato, Aldo
AU - Galli, Luca
AU - Morganti, Riccardo
AU - Chiacchio, Serena
AU - Marciano, Andrea
AU - Zanca, Roberta
AU - Mannelli, Lorenzo
AU - Coraggio, Gabriele
AU - Sbrana, Andrea
AU - Cocuzza, Paola
AU - Montrone, Sabrina
AU - Baldaccini, Davide
AU - Gonnelli, Alessandra
AU - Molinari, Alessandro
AU - Cantarella, Martina
AU - Mazzotti, Valentina
AU - Ricci, Sergio
AU - Paiar, Fabiola
AU - Erba, Paola Anna
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Background: In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [18F]Fluoro-Methyl Choline ([18F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT). Methods: Patients with biochemical recurrence limited up to three lesions revealed by [18F]FMCH PET/CT were enrolled in the present study and treated with SBRT on all active lesions. Systemic therapy-free survival since the [18F]FMCH PET/CT was considered as the primary endpoint. Results: Forty-six patients were evaluated, and a total of 67 lesions were treated. After a median follow-up of 28.9 months, systemic therapy was started in 30 patients (65.2%) and median systemic therapy-free survival was 39.1 months (95% CI 6.5–68.6); 6, 12, and 24-month ratios were 93.5%, 73.9%, and 63.1%, respectively. At univariate Cox regression analysis, Delta PSA demonstrated an impact on systemic therapy-free survival (p < 0.001). Conclusions: Based on our findings, [18F]FMCH PET/CT can identify oligometastatic prostate cancer patients suitable for SBRT, resulting in a systemic therapy-free survival of 39.1 months.
AB - Background: In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [18F]Fluoro-Methyl Choline ([18F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT). Methods: Patients with biochemical recurrence limited up to three lesions revealed by [18F]FMCH PET/CT were enrolled in the present study and treated with SBRT on all active lesions. Systemic therapy-free survival since the [18F]FMCH PET/CT was considered as the primary endpoint. Results: Forty-six patients were evaluated, and a total of 67 lesions were treated. After a median follow-up of 28.9 months, systemic therapy was started in 30 patients (65.2%) and median systemic therapy-free survival was 39.1 months (95% CI 6.5–68.6); 6, 12, and 24-month ratios were 93.5%, 73.9%, and 63.1%, respectively. At univariate Cox regression analysis, Delta PSA demonstrated an impact on systemic therapy-free survival (p < 0.001). Conclusions: Based on our findings, [18F]FMCH PET/CT can identify oligometastatic prostate cancer patients suitable for SBRT, resulting in a systemic therapy-free survival of 39.1 months.
KW - Prostate cancer
KW - Stereotactic body radiotherapy
KW - [F]FMCH PET/CT
UR - http://www.scopus.com/inward/record.url?scp=85074045009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074045009&partnerID=8YFLogxK
U2 - 10.1007/s00259-019-04482-6
DO - 10.1007/s00259-019-04482-6
M3 - Article
C2 - 31620808
AN - SCOPUS:85074045009
VL - 47
SP - 185
EP - 191
JO - European Journal of Pediatrics
JF - European Journal of Pediatrics
SN - 0340-6199
IS - 1
ER -